ABL Diagnostics announced that it has been selected by the Évry Commercial Court to acquire the assets and business operations of TEXCELL, a company with expertise in viral safety, biosafety, genomic analysis, and immunological monitoring for biotechnology and innovative therapies. The selection follows an industrial plan submitted by ABL Diagnostics aimed at ensuring business continuity and preserving TEXCELL’s scientific expertise.
The transaction includes the transfer of 29 employees, comprising 23 permanent staff and 6 apprentices or trainees, and the continuation of operations at the Genopole site in Évry-Courcouronnes. ABL Diagnostics will assume accrued employee rights for the transferred staff totaling €91,829.24, subject to final adjustment. According to publicly available information, TEXCELL France generated revenue of approximately €5.4 million in 2024, down from €6.2 million in 2023 and €7.5 million in 2022.
The overall economic value of the project is estimated at approximately €2.9 million, including a €225,000 purchase price for assets, €30,000 for inventory, roughly €100,000 for reconstitution of security deposits, future lease installments of €531,792.74 for operational equipment, an estimated €930,000 industrial and technological investment program, and an estimated $1,000,000 increase in working capital requirements to support the acquired activities. The company said the transaction will be financed from the group’s available financial resources.
TEXCELL originated from the scientific ecosystem of the Institut Pasteur, and ABL Diagnostics said the acquisition builds on its existing strategic initiatives with the institute, including an HPV RNA-Seq genotyping project. The company said TEXCELL’s expertise in viral safety, biological control, cell culture, and biosafety complements its existing UltraGene, DeepChek, and Nadis platforms, and it plans to add approximately five employees at the Genopole site to support TEXCELL’s scientific activities.
KEY QUOTE:
“TEXCELL brings ABL Diagnostics recognized scientific expertise, qualified teams, an established international brand, as well as technological and biological assets that complement our historical activities. This acquisition strengthens our presence in the fields of virology, biosafety, and services dedicated to biopharmaceutical companies. This transaction is fully aligned with ABL Diagnostics’ long-term strategy to strengthen its position among the leading international players in molecular biology, virology, and infectious diseases.”
Dr. Chalom Sayada, Chief Executive Officer, ABL Diagnostics
